Skip to main content

Table 4 Overview of the literature focusing on external radiotherapy for anal canal carcinoma

From: Interstitial high-dose rate brachytherapy as boost for anal canal cancer

Authors (Year) EBT type # pts Median FU (months) Median EBRT dose (Gy) LR OS (%) Colostomy Late toxicity ≥ G3 [%]
Initial Boost LRR (%) LCR (%) CR % CFS %
Northover et al. (2010) [5] 2DRT 290 157 45 N/A 57.1 (5 y) 33.7 (5 y) 53 (5 y)   36.8 (5 y) N/A
Northover et al. (2010) [5] 2DRT + CT 295 157 45 N/A 32.3 (5 y) 46.6 (5 y) 58.1 (5 y)   46.9 (5 y) N/A
Ajani et al. (2008) [23] 2DRT MMC-arm 324 30 45 10-14 25 (5 y)   84% (5 y) 10% (5y)   11%
Kachnic et al. (2013) [24] IMRT 43 24 42* 50.4*   95% (2 y) 94% (2 y)   90% (2 y) 7%
50.4** 54**
  1. *For T1-T2 : 42 Gy with 50.4 Gy integrated boost on the tumor volume.
  2. **For T3-T4 : 50.4 Gy with 54 Gy integrated boost on the tumor volume.
  3. EBT: external beam radiation therapy; # pts: number of patients; FU: follow-up; LR: local recurrence; LRR: local recurrence rate; LCR: local control rate; OS: overall survival; CR: colostomy rate; CFS : colostomy free survival; NA: non-applicable; DSS: disease specific survival; 2DRT: 2 dimension radiation therapy; CT: chemotherapy; MMC: Mitomycin-C; IMRT: intensity modulated radiation therapy; N/A: not applicable.